Tamim M Nazif1, Shmuel Chen2, Isaac George1, Jose M Dizon1, Rebecca T Hahn1, Aaron Crowley2, Maria C Alu1, Vasilis Babaliaros3, Vinod H Thourani4, Howard C Herrmann5, Richard W Smalling6, David L Brown7, Michael J Mack7, Samir Kapadia8, Raj Makkar9, John G Webb10, Martin B Leon1, Susheel K Kodali1. 1. Columbia University Irving Medical Center/New York-Presbyterian Hospital, 177 Fort Washington Avenue, 5th Floor, Room 5C-501, New York, NY, USA. 2. Cardiovascular Research Foundation, New York, NY, USA. 3. Emory University School of Medicine, Atlanta, GA, USA. 4. Medstar Heart & Vascular Institute/Washington Hospital Center, Washington, DC, USA. 5. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6. University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 7. Baylor Scott & White Health, Plano, TX, USA. 8. Cleveland Clinic, Cleveland, OH, USA. 9. Cedars Sinai Medical Center, Los Angeles, CA, USA. 10. St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Abstract
AIMS: Transcatheter aortic valve replacement (TAVR) is now an established therapy for intermediate-risk surgical candidates with symptomatic, severe aortic stenosis. The clinical impact of new-onset left bundle branch block (LBBB) after TAVR remains controversial and has not been studied in intermediate-risk patients. We therefore sought to analyse outcomes associated with new LBBB in a large cohort of intermediate-risk patients treated with TAVR. METHODS AND RESULTS: A total of 2043 patients underwent TAVR in the PARTNER II trial and S3 intermediate-risk registry and survived to hospital discharge. Patients were excluded from the current analysis due to baseline conduction disturbances, pre-existing permanent pacemaker (PPM), and new PPM during the index hospitalization. Clinical outcomes at 2 years were compared between patients with and without persistent, new-onset LBBB at hospital discharge, and multivariable analysis was performed to identify predictors of mortality. Among 1179 intermediate-risk patients, new-onset LBBB at discharge occurred in 179 patients (15.2%). Patients with new LBBB were similar to those without except for more frequent diabetes and more frequent treatment with SAPIEN 3 vs. SAPIEN XT. At 2 years, new LBBB was associated with increased rates of all-cause mortality (19.3% vs. 10.8%, P = 0.002), cardiovascular mortality (16.2% vs. 6.5%, P < 0.001), rehospitalization, and new PPM implantation. By multivariable analysis, new LBBB remained an independent predictor of 2-year all-cause [hazard ratio (HR) 1.98, 95% confidence interval (95% CI) 1.33, 2.96; P < 0.001] and cardiovascular (HR 2.66 95% CI 1.67, 4.24; P < 0.001) mortality. New LBBB was also associated with worse left ventricular systolic function at 1 and 2-year follow-up. CONCLUSIONS: In a large cohort of intermediate-risk patients from the PARTNER II trial and registry, persistent, new-onset LBBB occurred in 15.2% of patients without baseline conduction disturbances or pacemaker. New LBBB was associated with adverse clinical outcomes at 2 years, including all-cause and cardiovascular mortality, rehospitalization, new pacemaker implantation, and worsened left ventricular systolic function. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov #NCT01314313 and NCT03222128. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Transcatheter aortic valve replacement (TAVR) is now an established therapy for intermediate-risk surgical candidates with symptomatic, severe aortic stenosis. The clinical impact of new-onset left bundle branch block (LBBB) after TAVR remains controversial and has not been studied in intermediate-risk patients. We therefore sought to analyse outcomes associated with new LBBB in a large cohort of intermediate-risk patients treated with TAVR. METHODS AND RESULTS: A total of 2043 patients underwent TAVR in the PARTNER II trial and S3 intermediate-risk registry and survived to hospital discharge. Patients were excluded from the current analysis due to baseline conduction disturbances, pre-existing permanent pacemaker (PPM), and new PPM during the index hospitalization. Clinical outcomes at 2 years were compared between patients with and without persistent, new-onset LBBB at hospital discharge, and multivariable analysis was performed to identify predictors of mortality. Among 1179 intermediate-risk patients, new-onset LBBB at discharge occurred in 179 patients (15.2%). Patients with new LBBB were similar to those without except for more frequent diabetes and more frequent treatment with SAPIEN 3 vs. SAPIEN XT. At 2 years, new LBBB was associated with increased rates of all-cause mortality (19.3% vs. 10.8%, P = 0.002), cardiovascular mortality (16.2% vs. 6.5%, P < 0.001), rehospitalization, and new PPM implantation. By multivariable analysis, new LBBB remained an independent predictor of 2-year all-cause [hazard ratio (HR) 1.98, 95% confidence interval (95% CI) 1.33, 2.96; P < 0.001] and cardiovascular (HR 2.66 95% CI 1.67, 4.24; P < 0.001) mortality. New LBBB was also associated with worse left ventricular systolic function at 1 and 2-year follow-up. CONCLUSIONS: In a large cohort of intermediate-risk patients from the PARTNER II trial and registry, persistent, new-onset LBBB occurred in 15.2% of patients without baseline conduction disturbances or pacemaker. New LBBB was associated with adverse clinical outcomes at 2 years, including all-cause and cardiovascular mortality, rehospitalization, new pacemaker implantation, and worsened left ventricular systolic function. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov #NCT01314313 and NCT03222128. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ka Yan Lam; Naomi Timmermans; Ferdi Akca; Erwin Tan; Niels J Verberkmoes; Kim de Kort; Mohamed Soliman-Hamad; Albert H M van Straten Journal: Interact Cardiovasc Thorac Surg Date: 2021-05-10
Authors: Harish Appa; Kenneth Park; Deon Bezuidenhout; Braden van Breda; Bruce de Jongh; Jandré de Villiers; Reno Chacko; Jacques Scherman; Chima Ofoegbu; Justiaan Swanevelder; Michael Cousins; Paul Human; Robin Smith; Ferdinand Vogt; Bruno K Podesser; Christoph Schmitz; Lenard Conradi; Hendrik Treede; Holger Schröfel; Theodor Fischlein; Martin Grabenwöger; Xinjin Luo; Heather Coombes; Simon Matskeplishvili; David F Williams; Peter Zilla Journal: Front Cardiovasc Med Date: 2022-03-03
Authors: Thomas T Poels; Robert Stassen; Suzanne Kats; Leo Veenstra; Vincent van Ommen; Bastiaan Kietselaer; Patrick Houthuizen; Jos G Maessen; Frits W Prinzen Journal: Medicina (Kaunas) Date: 2021-05-11 Impact factor: 2.430
Authors: Mohammed Saad; Yannic Klaus; Paul Buhse; Thomas Puehler; Georg Lutter; Hatim Seoudy; Derk Frank Journal: Herzschrittmacherther Elektrophysiol Date: 2021-07-14